CN114053271B - 一种含有tsl-1502m的药物组合物及其应用 - Google Patents
一种含有tsl-1502m的药物组合物及其应用 Download PDFInfo
- Publication number
- CN114053271B CN114053271B CN202010747965.2A CN202010747965A CN114053271B CN 114053271 B CN114053271 B CN 114053271B CN 202010747965 A CN202010747965 A CN 202010747965A CN 114053271 B CN114053271 B CN 114053271B
- Authority
- CN
- China
- Prior art keywords
- tsl
- pharmaceutical composition
- hydroxycamptothecin
- ethyl
- pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 31
- 239000007924 injection Substances 0.000 claims abstract description 24
- 238000002347 injection Methods 0.000 claims abstract description 24
- 238000002360 preparation method Methods 0.000 claims abstract description 22
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 239000002552 dosage form Substances 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 42
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 38
- 229940079593 drug Drugs 0.000 claims description 23
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 19
- 229930195725 Mannitol Natural products 0.000 claims description 19
- 239000000594 mannitol Substances 0.000 claims description 19
- 235000010355 mannitol Nutrition 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 8
- 239000000463 material Substances 0.000 claims description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
- 239000008101 lactose Substances 0.000 claims description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims 1
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 abstract description 32
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract description 26
- 229960004768 irinotecan Drugs 0.000 abstract description 24
- 239000002246 antineoplastic agent Substances 0.000 abstract description 17
- 229940041181 antineoplastic drug Drugs 0.000 abstract description 17
- 150000001875 compounds Chemical class 0.000 abstract description 15
- 229960004964 temozolomide Drugs 0.000 abstract description 14
- 238000005516 engineering process Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 39
- 230000005764 inhibitory process Effects 0.000 description 34
- 238000007789 sealing Methods 0.000 description 24
- FDLYAMZZIXQODN-UHFFFAOYSA-N olaparib Chemical compound FC1=CC=C(CC=2C3=CC=CC=C3C(=O)NN=2)C=C1C(=O)N(CC1)CCN1C(=O)C1CC1 FDLYAMZZIXQODN-UHFFFAOYSA-N 0.000 description 22
- 238000004806 packaging method and process Methods 0.000 description 20
- 229960000572 olaparib Drugs 0.000 description 19
- 230000035755 proliferation Effects 0.000 description 19
- 229960000303 topotecan Drugs 0.000 description 19
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 19
- 239000007864 aqueous solution Substances 0.000 description 17
- 230000000694 effects Effects 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- 238000009924 canning Methods 0.000 description 16
- 238000004108 freeze drying Methods 0.000 description 16
- 238000001291 vacuum drying Methods 0.000 description 16
- 239000000843 powder Substances 0.000 description 12
- 238000002156 mixing Methods 0.000 description 11
- 230000002195 synergetic effect Effects 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 239000012074 organic phase Substances 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 229950011257 veliparib Drugs 0.000 description 9
- JNAHVYVRKWKWKQ-CYBMUJFWSA-N veliparib Chemical compound N=1C2=CC=CC(C(N)=O)=C2NC=1[C@@]1(C)CCCN1 JNAHVYVRKWKWKQ-CYBMUJFWSA-N 0.000 description 9
- 206010006187 Breast cancer Diseases 0.000 description 8
- 208000026310 Breast neoplasm Diseases 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000012661 PARP inhibitor Substances 0.000 description 7
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 7
- 206010009944 Colon cancer Diseases 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 230000000259 anti-tumor effect Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 239000000825 pharmaceutical preparation Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 4
- 208000029742 colonic neoplasm Diseases 0.000 description 4
- 239000000945 filler Substances 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 239000002207 metabolite Substances 0.000 description 4
- 239000012071 phase Substances 0.000 description 4
- -1 plasters Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000003826 tablet Substances 0.000 description 4
- 108700020463 BRCA1 Proteins 0.000 description 3
- 102000036365 BRCA1 Human genes 0.000 description 3
- 101150072950 BRCA1 gene Proteins 0.000 description 3
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 description 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 238000011049 filling Methods 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- 108091007743 BRCA1/2 Proteins 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QPMSXSBEVQLBIL-CZRHPSIPSA-N ac1mix0p Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1.O([C@H]1[C@]2(OC)C=CC34C[C@@H]2[C@](C)(O)CCC)C2=C5[C@]41CCN(C)[C@@H]3CC5=CC=C2O QPMSXSBEVQLBIL-CZRHPSIPSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 210000004748 cultured cell Anatomy 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 description 2
- 229950011068 niraparib Drugs 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 229950004707 rucaparib Drugs 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- APWNJAHVEIVNTL-PQVHYZHUSA-N (2s,3s,4s,5r,6s)-3,4,5-trihydroxy-6-[[3-methyl-1-[(3s)-1-propylpyrrolidin-3-yl]-6,7,8,9-tetrahydropyrazolo[3,4-c]isoquinolin-5-yl]oxy]oxane-2-carboxylic acid Chemical compound C1N(CCC)CC[C@@H]1C1=NN(C)C2=NC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)=C(CCCC3)C3=C12 APWNJAHVEIVNTL-PQVHYZHUSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- SHKSWTUELIHTPG-UHFFFAOYSA-N 1h-imidazole;tetrazine Chemical class C1=CNC=N1.C1=CN=NN=N1 SHKSWTUELIHTPG-UHFFFAOYSA-N 0.000 description 1
- JNAHVYVRKWKWKQ-UHFFFAOYSA-N 2-(2-methyl-2-pyrrolidinyl)-1H-benzimidazole-4-carboxamide Chemical compound N=1C2=C(C(N)=O)C=CC=C2NC=1C1(C)CCCN1 JNAHVYVRKWKWKQ-UHFFFAOYSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- QUZPSMZNTIBYAS-UHFFFAOYSA-N 4-benzoylperoxy-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)OOC(=O)C1=CC=CC=C1 QUZPSMZNTIBYAS-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102100034533 Histone H2AX Human genes 0.000 description 1
- 101710195517 Histone H2AX Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 208000005016 Intestinal Neoplasms Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 102000006833 Multifunctional Enzymes Human genes 0.000 description 1
- 108010047290 Multifunctional Enzymes Proteins 0.000 description 1
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 description 1
- 102100023652 Poly [ADP-ribose] polymerase 2 Human genes 0.000 description 1
- 101710144590 Poly [ADP-ribose] polymerase 2 Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 208000009125 Sigmoid Neoplasms Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010043515 Throat cancer Diseases 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- XDVMCVGTDUKDHL-UHFFFAOYSA-N [amino(2-azaniumylethylsulfanyl)methylidene]azanium;dibromide Chemical compound Br.Br.NCCSC(N)=N XDVMCVGTDUKDHL-UHFFFAOYSA-N 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 201000005188 adrenal gland cancer Diseases 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 208000036815 beta tubulin Diseases 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 201000006491 bone marrow cancer Diseases 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- UDSAIICHUKSCKT-UHFFFAOYSA-N bromophenol blue Chemical compound C1=C(Br)C(O)=C(Br)C=C1C1(C=2C=C(Br)C(O)=C(Br)C=2)C2=CC=CC=C2S(=O)(=O)O1 UDSAIICHUKSCKT-UHFFFAOYSA-N 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 1
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 210000000448 cultured tumor cell Anatomy 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 239000008157 edible vegetable oil Substances 0.000 description 1
- 230000000431 effect on proliferation Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002662 enteric coated tablet Substances 0.000 description 1
- 229940125532 enzyme inhibitor Drugs 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 208000024519 eye neoplasm Diseases 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 201000010235 heart cancer Diseases 0.000 description 1
- 208000024348 heart neoplasm Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 208000029824 high grade glioma Diseases 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 230000005918 in vitro anti-tumor Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 239000012160 loading buffer Substances 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 201000010453 lymph node cancer Diseases 0.000 description 1
- 229940100352 lynparza Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- ODLHGICHYURWBS-FOSILIAISA-N molport-023-220-444 Chemical compound CC(O)COC[C@@H]([C@@H]([C@H]([C@@H]1O)O)O[C@@H]2O[C@H]([C@H](O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O[C@@H]3O[C@@H](COCC(C)O)[C@@H]([C@H]([C@@H]3O)O)O3)[C@@H](O)[C@@H]2O)COCC(O)C)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@H]3O[C@H]1COCC(C)O ODLHGICHYURWBS-FOSILIAISA-N 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 201000008106 ocular cancer Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000005443 oral cavity cancer Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 229940043267 rhodamine b Drugs 0.000 description 1
- HMABYWSNWIZPAG-UHFFFAOYSA-N rucaparib Chemical compound C1=CC(CNC)=CC=C1C(N1)=C2CCNC(=O)C3=C2C1=CC(F)=C3 HMABYWSNWIZPAG-UHFFFAOYSA-N 0.000 description 1
- INBJJAFXHQQSRW-STOWLHSFSA-N rucaparib camsylate Chemical compound CC1(C)[C@@H]2CC[C@@]1(CS(O)(=O)=O)C(=O)C2.CNCc1ccc(cc1)-c1[nH]c2cc(F)cc3C(=O)NCCc1c23 INBJJAFXHQQSRW-STOWLHSFSA-N 0.000 description 1
- 201000003825 sigmoid colon cancer Diseases 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229910052938 sodium sulfate Inorganic materials 0.000 description 1
- 235000011152 sodium sulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000007940 sugar coated tablet Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及一种含有TSL‑1502M的药物组合物及其应用,所述药物组合物是由化合物TSL‑1502M和替莫唑胺或伊立替康组成的复方药物组合物,本发明还包括所述药物组合物的制备方法,包括将含有效量的TSL‑1502M和有效量的另外一种抗肿瘤药物一起或分别作为药物活性成分,根据制剂学常规技术制备成可供服用的药物组合物,其剂型包括,注射剂,本发明对TSL‑1502M和其他药物的联合应用进行了研究,意外的发现,TSL‑1502M和替莫唑胺,7‑乙基‑10‑羟基喜树碱、伊立替康、拓扑替康联合使用具有协同增效作用。
Description
技术领域
本发明属于药物制备技术领域,具体涉及一种含有PARP抑制剂TSL-1502的中间体TSL-1502M的药物组合物及其应用。
背景技术
PARP抑制剂TSL-1502,化学名为(2S,3S,4S,5R,6S)-3,4,5-三羟基-6-(3-甲基-1-((S)-1-丙基吡咯烷-3-基)-6,7,8,9-四氢-3H-吡唑并[3,4-c]异喹啉-5-氧基)四氢-2H-吡喃-2-甲酸的化合物(设定其编号为TSL-1502),该化合物最早出现在201180002886.8(公开号为CN102510863A,授权公告号为CN102510863B,以下简称为2011年专利)的0177段化合物,其结构式见式Ⅰ。
上述专利在权利要求16公开了具体肿瘤类型,如头部癌、甲状腺癌、颈癌、眼癌、皮肤癌、口腔癌、咽喉癌、食道癌、胸癌、骨癌、血癌、骨髓癌、肺癌、结肠癌、乙状结肠癌、直肠癌、胃癌、前列腺癌、乳腺癌、卵巢癌、肾癌、肝癌、胰腺癌、脑癌、肠癌、心脏癌、肾上腺癌、皮下组织癌、淋巴结癌、色素癌、恶性神经胶质瘤等。然而实际上,也仅在实施例19证实了黑色素瘤、人乳腺癌细胞株的治疗效果,对其他肿瘤没有涉及。
TSL-1502M,是制备TSL-1502的中间体,其申请号为201910465780.X,发明名称为一种PARP抑制剂的中间体TSL-1502M及其制备方法,(申请日为2019年05月31日,尚未公开),结构式见式Ⅱ,
式Ⅱ化合物设定其编号为:TSL-1502M,其作为中间体即可以用于制备TSL-1502,又可以用于TSL-1502的检测,作为对照品是有用的。但是该文献中并没有公开TSL-1502M的药物用途信息及与其他抗癌药物组合的相关信息。
发明人在研究TSL-1502M时,意外发现其对PARP酶的抑制活性高于TSL-1502,提示了其作为PARP抑制剂的药物用途。
TSL-1502M和其他药物联合应用未见报道,本发明对TSL-1502M和其他药物的联合应用进行了研究,意外的发现,其和替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康联合使用具有协同增效作用。
发明内容
本发明提供一种含有TSL-1502M和另外一种抗肿瘤药物的复方药物组合物,其中,所述TSL-1502M结构如下
其中所述另外一种抗肿瘤药物选自替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康。
本发明包括含有TSL-1502M和另外一种抗肿瘤药物两种活性成分的药物制剂组合物,或分立的含有TSL-1502M和另外一种抗肿瘤药物的药物制剂,两种制剂包装在一起的组合。
本发明所述的药物组合物的制备包括将含有TSL-1502M和另外一种抗肿瘤药物混合的步骤。
或将含有TSL-1502M和另外一种抗肿瘤药物分别制备成药物制剂,将两种制剂组合包装在一起,使用时可以方便的联合应用两种药物。如所述组合包装可以将TSL-1502M制备成注射剂,另外一种抗肿瘤药物制备成注射剂,两种单位剂量的注射剂一起包装在同一个包装盒中,使用时可以分别注射,也可以一起注射。
本发明所述的TSL-1502M和另外一种抗肿瘤药物的药物组合物,其中每一种药物的剂量采用药物有效量,所述“有效量”是指每一种药物单独或联合应用时能够实现临床上预防或治疗疾病而起效的量。如制备成注射剂,是单位剂量形式,如分装成不同颜色,不同规格大小的无菌小瓶,每瓶含有药物活性成分0.1-2000mg,小瓶封装后,再置入包装盒子中;还可进一步置入可装有2-100瓶的包装盒子中,方便储存和运输。
本发明所述组药物合物包含TSL-1502M和另外一种抗肿瘤药物,两者重量比可以根据各自的有效量进行配比,如为1∶1000至1000∶1。
对于乳腺癌,TSL-1502M和替莫唑胺的重量比为3-10nm:10-30μm,优选为3nm:10-30μm。
对于大肠癌或结肠癌,TSL-1502M和7-乙基-10-羟基喜树碱或伊立替康的重量为3-10μM:0.1-1nM,优选为3-10μM:0.1nM。
本发明所述的药物组合物的制备方法,包括将含所需量的TSL-1502M和另外一种抗肿瘤药物一起或分别作为药物活性成分,根据制剂学常规技术制备成可供服用的药物制剂组合物,其剂型包括,注射剂,优选干粉注射剂,特别优选冷冻干燥注射剂。
本发明的注射剂可以不加入辅料或加入一种或多种药用辅料,如:葡萄糖,乳糖,甘露醇,氯化钠,羟丙基-B-环糊精等,然后使用适当的方法制成注射剂。
本发明的使用方法包括,将含所需量的TSL-1502M和另外一种抗肿瘤药物一起作为两种药物活性成分制备成注射剂一起注射使用。也可将含所需量的TSL-1502M和另外一种抗肿瘤药物分别作成注射剂,分别注射使用。
本发明所述药物制剂组合物,可以是任何可服用的药物形式:如:片剂、糖衣片剂、薄膜衣片剂、肠溶衣片剂、胶囊剂、硬胶囊剂、软胶囊剂、口服液、口含剂、颗粒剂、冲剂、丸剂、散剂、膏剂、丹剂、混悬剂、粉剂、溶液剂、注射剂、栓剂、软膏剂、硬膏剂、霜剂、喷雾剂、滴剂、贴剂。
本发明的药物制剂组合物,优选的是单位剂量的药物制剂形式,如在制成药剂时,单位剂量的药剂可含有本发明的TSL-1502M,以及另外一种抗肿瘤药物0.1-1000mg,其余为药学上可接受的辅料。药学上可接受的辅料以重量计可以是制剂总重量的0.01-99.99%。
本发明的药物制剂组合物在使用时根据病人的情况确定用法用量,如一日1-3次。一次1-20片等。
优选的,本发明的药物制剂组合物为口服制剂或注射剂。其中,所述口服制剂选自胶囊剂、片剂、滴丸、颗粒剂、浓缩丸、口服液中的一种。其中,所述注射剂选自液体、半固体,固体,粉剂形式,优选注射液,粉针中的一种。
本发明的药物制剂组合物,其口服给药的制剂可含有辅料,诸如粘合剂、填充剂、稀释剂、压片剂、润滑剂、崩解剂、着色剂、调味剂和湿润剂,必要时可对片剂进行包衣。
适用的填充剂包括纤维素、甘露糖醇、乳糖和其它类似的填充剂。适宜的崩解剂包括淀粉、聚乙烯吡咯烷酮和淀粉衍生物,例如羟基乙酸淀粉钠。适宜的润滑剂包括,例如硬脂酸镁。适宜的药物可接受的湿润剂包括十二烷基硫酸钠。本发明的药物制剂可通过混合,填充,压片等常用的方法制备固体口服组合物。进行反复混合可使活性物质分布在整个使用大量填充剂的那些组合物中。口服液体制剂的形式例如可以是水性或油性悬浮液、溶液、乳剂、糖浆剂或酏剂,或者可以是一种在使用前可用水或其它适宜的载体复配的干燥产品。这种液体制剂可含有常规的添加剂,诸如悬浮剂,例如山梨醇、糖浆、甲基纤维素、明胶、羟乙基纤维素、羧甲基纤维素、硬脂酸铝凝胶或氢化食用脂肪,乳化剂,例如卵磷脂、脱水山梨醇一油酸酯或阿拉伯胶;非水性载体(它们可以包括食用油),例如杏仁油、分馏椰子油、诸如甘油的酯的油性酯、丙二醇或乙醇;防腐剂,例如对羟基苯甲酯或对羟基苯甲酸丙酯或山梨酸,并且如果需要,可含有常规的香味剂或着色剂。
对于注射剂,制备的液体单位剂型含有本发明的活性物质和无菌载体。根据载体和浓度,可以将此化合物悬浮或者溶解。溶液的制备通常是通过将活性物质溶解在一种载体中,在将其装入一种适宜的小瓶或安瓿前过滤消毒,然后密封。辅料例如一种局部麻醉剂、防腐剂和缓冲剂也可以溶解在这种载体中。为了提高其稳定性,可在装入小瓶以后将这种组合物冰冻,并在真空下将水除去。
本发明进一步提供本发明的组合物在制备抗肿瘤药物中的应用,所述应用时,TSL-1502M和另外一种抗肿瘤药物的使用剂量可以是一天0.01mg-2000mg。
本发明的应用取得了意想不到的技术效果,有关应用的实例见本发明实验例。
本发明提供的抗肿瘤的药物组合,具有以下特点:
1、发明人试验发现,TSL-1502M明显增效替莫唑胺对MDA-MB-436细胞(乳腺癌细胞株)的增殖抑制作用;与替莫唑胺合用后诱导MDA-MB-436细胞的γ-H2AX磷酸化水平显著增加,促进肿瘤细胞的细胞凋亡过程。
2、TSL-1502M与替莫唑胺合用后,对肿瘤细胞的抑制作用优于单独使用TSL-1502M或替莫唑胺,如表3-1所示,单独给予TSL-1502M在浓度为30nM时对MDA-MB-436细胞(乳腺癌)的抑制率为67.5±1.5%,单独使用TMZ在30μM时的抑制率为8.5±3.5%,二者联合可进一步将MDA-MB-436细胞增殖抑制率提高到80.2±3.5%,这种协同增效作用在较低的药物浓度时更为明显。
3、TSL-1502M明显增效伊立替康活性代谢产物SN38对SW620细胞(结肠癌细胞株)的增殖抑制作用。
4、TSL-1502M与伊立替康活性代谢产物SN38合用,对肿瘤细胞的抑制作用优于单独使用TSL-1502M或替莫唑胺。如表3-2所示,单独给予TSL-1502M在浓度为10μM时对SW620细胞(大肠癌,具体为结肠癌)的抑制率为37.2±17.9%,单独使用SN38(伊立替康的活性代谢物)在1nM时的抑制率为62.3±18.1%,二者联合可进一步将MDA-MB-436细胞增殖抑制率提高到98.3±1.3%,这种协同增效作用在较低的药物浓度时更为明显。
附图说明
图1:TSL-1502及TSL-1502M对体外培养细胞增殖的影响
图2:TSL-1502、TSL-1502M与细胞毒药物合用对MDA-MB-436、SW620细胞增殖的抑制作用;
图3:TSL-1502M对MDA-MB-436细胞γ-H2AX磷酸化的影响。
具体实施方式
实施例1
本发明提供TSL-1502M和另外一种抗肿瘤药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康组成的复方药物冷冻干燥注射剂,
制备实例:
取TSL-1502M 20g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康10g,分别溶于含有100g甘露醇的1000ml水溶液中,分别罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
实施例2
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康10g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
或
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康20g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
或
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康50g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
或
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康100g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
或
取TSL-1502M 10g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康5g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
或
取TSL-1502M 20g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康5g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
或
取TSL-1502M 50g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康5g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
或
取TSL-1502M 100g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康5g,共同溶于含有100g甘露醇的1000ml水溶液中,混合均匀,罐装到2g的小瓶中,共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,包装,即得。
实施例3
取TSL-1502M 2g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康1g,分别溶于含有100g甘露醇的1000ml水溶液中,分别罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
或
取TSL-1502M 10g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康5g,分别溶于含有100g甘露醇的1000ml水溶液中,分别罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
实施例4
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康2.5g,分别溶于含有100g甘露醇的1000ml水溶液中,罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
实施例5
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康5g,分别溶于含有100g甘露醇的1000ml水溶液中,分别罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
实施例6
取TSL-1502M 50g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康5g,分别溶于含有100g甘露醇的1000ml水溶液中,分别罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
实施例7
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康50g,分别溶于含有100g甘露醇的1000ml水溶液中,分别罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
实施例8
取TSL-1502M 5g,以及任选的以下任意一种药物替莫唑胺,7-乙基-10-羟基喜树碱、伊立替康、拓扑替康10g,分别溶于含有100g甘露醇的1000ml水溶液中,分别罐装到2g的小瓶中,各共计500瓶,封盖前,置入冷冻干燥箱中,真空干燥24小时,封盖,各取1瓶组合包装,即得。
实施例9:TSL-1502M的制备
参考申请号为201910465780.X,发明名称为一种PARP抑制剂的中间体TSL-1502M及其制备方法的实施例1:
反应:反应釜中,加入主原料(S)-3-甲基-1-(吡咯烷-3-基)-3,4,6,7,8,9-六氢-5H-吡唑并[3,4-c]异喹啉-5-酮(2S,3S)-2,3-二(苯甲酰氧基)丁二酸盐(630.0g,1mol)和乙醇(3800mL),搅拌,降温至10℃,加入氰基硼氢化钠(125.7g,2mol),再滴加丙醛(116.2g,2mol),滴加过程中温度不超过20℃,滴加完毕后,继续在10℃~25℃搅拌反应1h~2h。
淬灭:反应结束后,向反应混合物中缓慢滴加质量百分浓度为36~38%的盐酸(73g,2mol),调节pH至4-5之间,控制滴加速度,以20%氢氧化钠吸收大量冒出的气体,为防止冲料,同时控制温度为20℃~30℃。
后处理:S1、淬灭后的反应液减压浓缩蒸除乙醇,温度不超过70℃;
S2、向S1的残留物中加入水与二氯甲烷(水与二氯甲烷的重量比为1:4),使用量为式Ⅰ化合物重量的7倍,在5℃~15℃温度下用40%的氢氧化钠水溶液调节混合液的pH至9~10,搅拌,静置,分层,有机相保留;
S3、S2所得水相用二氯甲烷继续萃取1次,所得有机相与S2所得有机相合并,水相保留;
S4、S3所得合并后的有机相用40%的氢氧化钠水溶液萃取,所得水相与S3所得水相合并,有机相保留;
S5、S4所得合并后的水相用36~38%的盐酸调节pH至4~5,再加入二氯甲烷,二氯甲烷使用量为式Ⅰ化合物重量的5倍,搅拌后静置分层,有机相保留;
S6、S5所得水相用二氯甲烷继续萃取2次,所得有机相与S4、S5所得有机相合并;
S7、S6所得合并后的有机相用3%碳酸氢钠水溶液洗涤2次后再用无水硫酸钠干燥,过滤除去硫酸钠固体,滤液减压浓缩后真空干燥,得到PARP抑制剂的中间体TSL-1502M226g。
实验例1
一、实验材料
1、受试药物
TSL-1502:白色粉末,批号120301,纯度99.56%,含水量16.65%,密封,2-8℃保存,申请人自备;
TSL-1502M:白色粉末,批号20150801,纯度98.6%,密封,2-8℃保存,申请人自备;
ABT-888(维利帕尼,Veliparib):白色粉末,批号HM-069-8-20101112,纯度98.12%,密封,2-8℃保存,购自上海皓元公司,ABT-888是一种新型的强效PARP-1和PARP-2抑制剂,主要用于乳腺癌;
AZD2281(奥拉帕利,Olaparib):白色粉末,批号20131105,纯度99.15%,密封,2-8℃保存,购自上海德默公司,AZD2281是一种PARP抑制剂,已批准适应症包括卵巢癌、乳腺癌、胰腺癌、前列腺癌;
替莫唑胺(简称:TMZ):白色粉末,批号20150418,密封,2-8℃保存,替莫唑胺是咪唑四嗪衍生物,主要用于多形性胶质母细胞瘤;
SN-38(伊立替康的活性代谢物7-乙基-10-羟基喜树碱。cas号为86639-52-3):淡黄色粉末,纯度99.1%,批号E060206,密封,2-8℃保存,购自上海骏杰生物技术公司,伊立替康是喜树碱的半合成衍生物,主要用于结肠(直肠)癌。
2、药品配制方法:
TSL-1502、TSL-1502M、AZD2281和ABT-888用DMSO配成10mM的原液,分装保存于-70℃;TMZ用DMSO配成200mM的原液,分装保存于-70℃。
3、细胞株选择依据及细胞株来源
参考FDA批准上市的PARP抑制剂Olaparib(LYNPARZA)、Rucaparib(RUBRACA)和Niraparib(ZEJULA)的药效学研究情况,选择BRCA1/2突变型及野生型细胞来评价TSL-1502及其代谢产物的体外抗肿瘤活性。细胞来源及培养条件见表1
表1:细胞来源及类型
4、试剂及仪器
RPMI1640,L-15,F-10,DMEM及IMDM购自Gibco BRL公司;FBS购自Gibco BRL公司;SRB购自Sigma公司;抗Rad51一抗购自Santa Cruz公司;抗P-γ-H2AX和PARP一抗购自CellSignaling Technology公司;抗β-Tubulin一抗购自Sigma公司;辣根过氧化酶标记的羊抗兔和羊抗鼠二抗购自Calbiochem公司;Alexa488goat anti-rabbit荧光二抗购自Molecular Probes公司;Immobilon Western HRP Substrate luminal reagent购自Millipore公司;其它普通的化学试剂系国产分析纯(AR)试剂;
多功能酶标仪Synergy H4购自BioTek公司;二氧化碳培养箱(Model 3111)购自Thermo公司;倒置显微镜XDS-1B购自重庆光电仪器有限公司;流式细胞仪(FACS Caliburflow cytometer)购自Beckman Dickson公司;激光共聚焦显微镜购自奥林巴斯公司;Western blot成像仪购自GlinxScience instruments。
二、实验方法
1、磺酰罗丹明B蛋白染色法(SRB法)
接种一定数量的对数生长期细胞于96孔培养板。贴壁生长24小时后,加入不同浓度(1、3、10、30、100、300、1000、3000、10000nM)的药物。药物作用10天后,用三氯乙酸固定细胞。然后SRB溶液染色;最后加入Tris溶液溶解SRB,酶标仪510nm波长下测定OD值,以下列公式计算细胞生长抑制率:
抑制率=(OD值对照孔-OD值给药孔)/OD值对照孔×100%
根据各浓度抑制率,计算半数抑制浓度IC50。
2、Western blot法
γ-H2AX的磷酸化的检测:
MDA-MB-436接种于六孔板(2×105/ml),加入不同浓度的TSL-1502M或AZD2281(100、1000、10000nM)作用1.5小时后,再加入1mM TMZ作用0.5小时,加入1×SDS凝胶上样缓冲液(50mM Tris-HCl(pH 6.8),100mM DTT,2%SDS,10%甘油,0.1%溴酚蓝)裂解细胞。细胞裂解物在沸水浴中加热变性,进行SDS-PAGE电泳,电泳结束后,用湿转系统将蛋白转移至PVDF膜,将PVDF膜置于封闭液(5%脱脂奶粉稀释于TBS/T)中室温封闭,然后I,II抗反应;洗膜后,用Immobilon Western HRP Substrate luminal reagent试剂发色,Western blot成像仪拍照。
三、实验结果
1、TSL-1502、TSL-1502M抑制多种体外培养肿瘤细胞的增殖
TSL-1502、AZD2281、ABT-888作用于细胞240小时(120小时更换新配药物一次)后,检测其对细胞的增殖抑制作用。结果如表2和图1所示:
对BRCA基因缺陷或突变细胞(V-C8、MDA-MB-436、Capan-1和UWB1.289),TSL-1502M的增殖抑制作用十分显著,IC50分别为0.2±0.0nM、0.9±0.2nM、100.6±73.8nM、1.9±0.4nM),该抑制作用显著强于其前药TSL-1502(IC50分别为132.1±4.7nM、79.6±12.5nM、≈10000nM、935.7±526.6nM),以及参比药物AZD2281(IC50分别为18.6±1.3nM、4.0±0.7nM、586.1±89.4nM、≈1nM(抑制率稍弱于TSL-1502M))和ABT-888(IC50分别为314.2±24.4nM、114.7±60.8nM、NA、2102.5±1470.1nM);
但对BRCA1突变的HCC1937细胞,TSL-1502M、TSL-1502、AZD2281和ABT-888的增殖抑制均较弱。
对BRCA基因正常细胞(V-C8#13-5和UWB1.289 BRCA1),TSL-1502M、TSL-1502、AZD2281和ABT-888的增殖抑制作用均较弱;但对BRCA功能正常的MDA-MB-468细胞,TSL-1502M和AZD2281有一定增殖抑制作用(IC50分别为73.6±19.5nM和541.1±93.8nM)。
总体而言,TSL-1502M对BRCA1/2功能缺陷的细胞更为敏感,对细胞的增殖抑制作用具有选择性,其选择性的作用特点与AZD2281和ABT-888相似,其抑制作用比TSL-1502、AZD2281和ABT-888强。
表2:对体外培养细胞增殖的影响(n=2)
2、TSL-1502、TSL-1502M增效细胞毒药物抗肿瘤活性
检测了TSL-1502和TSL-1502M与细胞毒药物的联合抗肿瘤作用。结果如表3-1、3-2、3-3、3-4和图2所示。
2.1TSL-1502和TSL-1502M对MDA-MB-436细胞的增殖抑制作用:见表3-1
表3-1:对MDA-MB-436细胞增殖的抑制作用。抑制率(%,Mean±SD)
表3-2金氏公式计算TSL-1502M和TMZ两种药物的联合作用Q值
C1502M(nM) | CTMZ(μM) | Q | 协同作用 |
3 | 10 | 1.62 | 是 |
10 | 10 | 1.13 | 否 |
30 | 10 | 1.10 | 否 |
3 | 30 | 1.84 | 是 |
10 | 30 | 1.16 | 是 |
30 | 30 | 1.14 | 否 |
在BRCA1突变的MDA-MB-436细胞中,TSL-1502、TSL-1502M和参比化合物AZD2281、ABT-888均能够明显增效TMZ对MDA-MB-436细胞的增殖抑制作用。单独使用TMZ(≤30μM)对MDA-MB-436细胞的增殖几乎没有抑制作用,而10μM的TMZ与3nM的TSL-1502M联合使用时,Q值为1.62具有协同作用;30μM的TMZ与3nM或10nM的TSL-1502M联合使用时,Q值分别为1.84和1.16具有协同作用。即肿瘤细胞或肿瘤组织中TSL-1502M与TMZ的药物浓度分别在3-10nM和10-30μM范围内,对肿瘤的抑制具有协同作用,效果较佳的是TSL-1502M 3nM和TMZ 10-30μM,效果更佳的是TSL-1502M3nM和TMZ 30μM的组合。
2.2:TSL-1502和TSL-1502M对SW620细胞的增殖抑制作用。见表3-3
表3-3:对SW620细胞的增殖抑制作用。抑制率(%,Mean±SD)
表3-4金氏公式计算TSL-1502M和SN38两种药物的联合作用Q值
C1502M(μM) | C SN38(nM) | Q | 协同作用 |
3 | 1 | 1.41 | 是 |
10 | 1 | 1.29 | 是 |
3 | 0.1 | 2.01 | 是 |
10 | 0.1 | 1.51 | 是 |
在BRCA基因正常的SW620细胞中,TSL-1502M和参比化合物AZD2281均能够明显增效TMZ对SW620细胞的增殖抑制作用。单独给予SN38(≤1nM)或TSL-1502M(≤10μM),对SW620细胞的抑制率最高分别为62.3±18.1、37.2±17.9;当两者联合使用时,抑制率可提高到98.3±1.3%;TSL-1502M(3μM~10μM)和SN38(0.1nM~1nM)联合应用,Q值均大于1.15具有协同作用。
上述结果表明,在BRCA基因突变或正常的肿瘤细胞中,TSL-1502M对细胞毒药物均有增效作用。
3、TSL-1502M与TMZ合用明显增强MDA-MB-436细胞γ-H2AX的磷酸化
磷酸化的组蛋白H2AX(γ-H2AX)是DNA损伤的标志物,我们在BRCA1突变的MDA-MB-436细胞中检测了TSL-1502M与TMZ合用后对DNA损伤修复的影响。TSL-1502M以及参比对照化合物AZD2281合用TMZ后,对γ-H2AX的影响结果见图3,合用部分见图中圆圈的部分,结果显示:
TSL-1502M或参比化合物AZD2281与TMZ合用后γ-H2AX的磷酸化明显增强。
上述结果表明,TSL-1502M及AZD2281能抑制DNA损伤修复,TSL-1502M活性强于AZD2281。
试验结论:
TSL-1502M明显增效替莫唑胺对MDA-MB-436细胞(BRCA1突变)和伊立替康活性代谢产物SN38对SW620细胞(BRCA1/2正常)的增殖抑制作用;与替莫唑胺合用后诱导MDA-MB-436细胞的γ-H2AX磷酸化水平显著增加,提示协同增效作用通过促进肿瘤细胞的细胞凋亡而实现;TSL-1502M的作用特点与参比化合物AZD2281相似,TSL-1502M的活性比AZD2281强。
Claims (9)
1.一种含有TSL-1502M的药物组合物,由TSL-1502M和7-乙基-10-羟基喜树碱组成,其中,所述TSL-1502M结构如下:
2.根据权利要求1所述的药物组合物,包括含有TSL-1502M和7-乙基-10-羟基喜树碱两种活性成分的药物制剂组合物,或分立的含有TSL-1502M和7-乙基-10-羟基喜树碱的药物制剂,两种制剂包装在一起的组合。
3.根据权利要求1所述的药物组合物,是注射剂,单位剂量形式,每单位剂量含有药物活性成分0.1-2000mg。
4.根据权利要求1所述的药物组合物,包含TSL-1502M和7-乙基-10-羟基喜树碱,两者重量比为1∶1000至1000∶1。
5.根据权利要求1所述的药物组合物,其中每一种药物的剂量采用药物有效量。
6.根据权利要求1所述的药物组合物,是任何可服用的药物形式。
7.根据权利要求1所述的药物组合物,使用方法包括,将含所需量的TSL-1502M和7-乙基-10-羟基喜树碱一起作为两种药物活性成分制备成注射剂一起注射使用,也可将含所需量的TSL-1502M和7-乙基-10-羟基喜树碱分别作成注射剂,分别注射使用。
8.根据权利要求1-7任一项所述的药物组合物的制备方法,包括将含所需量的TSL-1502M和7-乙基-10-羟基喜树碱一起或分别作为药物活性成分,根据制剂学常规技术制备成可供服用的药物组合物。
9.根据权利要求8所述的制备方法,其剂型为注射剂其中可以不加入辅料或加入一种或多种药用辅料,所述辅料选自:葡萄糖,乳糖,甘露醇,氯化钠,羟丙基-β-环糊精,然后制成注射剂。
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010747965.2A CN114053271B (zh) | 2020-07-30 | 2020-07-30 | 一种含有tsl-1502m的药物组合物及其应用 |
PCT/CN2020/140555 WO2022021785A1 (zh) | 2020-07-30 | 2020-12-29 | 一种含有tsl-1502m的药物组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010747965.2A CN114053271B (zh) | 2020-07-30 | 2020-07-30 | 一种含有tsl-1502m的药物组合物及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114053271A CN114053271A (zh) | 2022-02-18 |
CN114053271B true CN114053271B (zh) | 2024-05-07 |
Family
ID=80037089
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010747965.2A Active CN114053271B (zh) | 2020-07-30 | 2020-07-30 | 一种含有tsl-1502m的药物组合物及其应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114053271B (zh) |
WO (1) | WO2022021785A1 (zh) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115073544A (zh) * | 2022-06-30 | 2022-09-20 | 上海应用技术大学 | 一种parp抑制剂吡唑并奎啉衍生物及其合成方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
CN101421268A (zh) * | 2006-02-15 | 2009-04-29 | 艾博特公司 | 作为有效parp抑制剂的吡唑并喹诺酮 |
CN102510863A (zh) * | 2010-05-24 | 2012-06-20 | 苏州汉德森医药科技有限公司 | 吡唑衍生物 |
CN102665711A (zh) * | 2009-12-23 | 2012-09-12 | 希格马托制药工业公司 | 青蒿素基药物与其他化学治疗剂的抗癌组合物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2008016339A (es) * | 2006-06-20 | 2009-01-16 | Abbott Lab | Pirazoloquinazolinonas en la forma de inhibidores parp. |
CN102850347B (zh) * | 2012-08-31 | 2015-08-05 | 苏州汉德景曦新药研发有限公司 | 一种吡唑衍生物或其盐的拆分方法 |
CN104945453B (zh) * | 2014-03-28 | 2018-06-26 | 江苏天士力帝益药业有限公司 | 吡唑衍生物的多晶型物 |
CA2992789A1 (en) * | 2015-08-20 | 2017-02-23 | Ipsen Biopharm Ltd. | Combination therapy using liposomal irinotecan and a parp inhibitor for cancer treatment |
-
2020
- 2020-07-30 CN CN202010747965.2A patent/CN114053271B/zh active Active
- 2020-12-29 WO PCT/CN2020/140555 patent/WO2022021785A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6465448B1 (en) * | 1999-08-13 | 2002-10-15 | Case Western Reserve University | Methoxyamine potentiation of temozolomide anti-cancer activity |
CN101421268A (zh) * | 2006-02-15 | 2009-04-29 | 艾博特公司 | 作为有效parp抑制剂的吡唑并喹诺酮 |
CN102665711A (zh) * | 2009-12-23 | 2012-09-12 | 希格马托制药工业公司 | 青蒿素基药物与其他化学治疗剂的抗癌组合物 |
CN102510863A (zh) * | 2010-05-24 | 2012-06-20 | 苏州汉德森医药科技有限公司 | 吡唑衍生物 |
Non-Patent Citations (3)
Title |
---|
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow;Todd A Hopkins et al;《Mol Cancer Res》;20190228;第17卷(第2期);第409-419页 * |
PARP抑制剂联合化疗药物治疗恶性肿瘤的研究进展;黄河等;《肿瘤》;20130430;第33卷(第4期);第372-377页 * |
聚腺苷二磷酸核糖聚合酶抑制剂在DNA修复通路与抗肿瘤中的作用;张舒等;《中国新药与临床杂志》;20141231;第33卷(第12期);第859-865页 * |
Also Published As
Publication number | Publication date |
---|---|
WO2022021785A1 (zh) | 2022-02-03 |
CN114053271A (zh) | 2022-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6239497B2 (ja) | Akt阻害剤化合物及びアビラテロンの組み合わせ、及び使用方法 | |
EP3472162B1 (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
EP1819331B1 (en) | Combinations comprising epothilones and protein tyrosine kinase inhibitors and pharmaceutical uses thereof | |
WO2014203129A1 (en) | Combinations of benzopyran compounds, compositions and uses thereof | |
US20090221488A1 (en) | Certain Compositions and Methods of Treatment | |
US10654867B2 (en) | Heteroaryl estrogen receptor modulators and uses thereof | |
CN104513257B (zh) | 取代脲衍生物及其在药物中的应用 | |
CN114053271B (zh) | 一种含有tsl-1502m的药物组合物及其应用 | |
CN106866690A (zh) | 三尖杉酯类生物碱、其制备方法和用途 | |
CN114053276B (zh) | 一种parp抑制剂tsl-1502中间体tsl-1502m的用途 | |
JP6373252B2 (ja) | オーロラキナーゼ阻害薬を使用する癌の治療方法 | |
CN108794478A (zh) | 新型嘌呤衍生物类化合物、其制备方法、药物组合物及其制药用途 | |
CN115403583A (zh) | 一种靶向降解fak蛋白的化合物及其用途 | |
CN117003737A (zh) | 取代的咪唑苯基甲酮类化合物及其衍生物和药物组合物 | |
EP3100734A1 (en) | Use of camptothecin derivative in preparing pharmaceutical used for treating multiple myeloma | |
SG185930A1 (en) | Pyrrolo [1,2-c] imidazole derivatives for use in the prophylaxis or treatment of cancer which is refractory to known cancer therapies | |
CN111821303A (zh) | 沃替西汀及其盐在制备抗肿瘤药物中的应用 | |
CN108218925B (zh) | 咪唑并吡啶类化合物钴配合物及其应用 | |
EP1485090B1 (en) | Combinations comprising an epothilone derivative and an imidazotetrazinone | |
KR101423134B1 (ko) | 신규한 판카스타틴 화합물 및 그를 유효성분으로 포함하는 조성물 | |
US20070286906A1 (en) | Dihydrobenzoquinone compounds | |
EP0357465A1 (en) | Pharmaceutical compositions for the treatment of occlusive vascular diseases | |
NZ617238B2 (en) | Combinations of akt inhibitor compounds and abiraterone, and methods of use | |
NZ617246B2 (en) | Combinations of akt inhibitor compounds and erlotinib, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40066075 Country of ref document: HK |
|
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |